68 related articles for article (PubMed ID: 38674115)
1. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
2. Imbalance between Actin Isoforms Contributes to Tumour Progression in Taxol-Resistant Triple-Negative Breast Cancer Cells.
Dugina V; Vasileva M; Khromova N; Vinokurova S; Shagieva G; Mikheeva E; Galembikova A; Dunaev P; Kudlay D; Boichuk S; Kopnin P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674115
[TBL] [Abstract][Full Text] [Related]
3. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
6. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis.
Shi M; Li Z; Shen G; Wang T; Li J; Wang M; Liu Z; Zhao F; Ren D; Zhao J
Cancer Pathog Ther; 2024 Apr; 2(2):81-90. PubMed ID: 38601487
[TBL] [Abstract][Full Text] [Related]
9. My battle with cancer. Part 1.
Blagosklonny MV
Oncoscience; 2024; 11():1-14. PubMed ID: 38188499
[TBL] [Abstract][Full Text] [Related]
10. Taxol acts differently on different tubulin isotypes.
Chew YM; Cross RA
Commun Biol; 2023 Sep; 6(1):946. PubMed ID: 37717119
[TBL] [Abstract][Full Text] [Related]
11. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities.
Kordias D; Kostara CE; Papadaki S; Verigos J; Bairaktari E; Magklara A
Cells; 2022 Aug; 11(17):. PubMed ID: 36078127
[TBL] [Abstract][Full Text] [Related]
12. Unique and redundant functions of cytoplasmic actins and nonmuscle myosin II isoforms at epithelial junctions.
Ivanov AI; Lechuga S; Marino-Melendez A; Naydenov NG
Ann N Y Acad Sci; 2022 Sep; 1515(1):61-74. PubMed ID: 35673768
[TBL] [Abstract][Full Text] [Related]
13. Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.
Krause W
Cancer Drug Resist; 2019; 2(1):82-106. PubMed ID: 35582143
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
